You are currently viewing the summary.
View Full TextLog in to view the full text
AAAS login provides access to Science for AAAS members, and access to other journals in the Science family to users who have purchased individual subscriptions.
More options
Download and print this article for your personal scholarly, research, and educational use.
Buy a single issue of Science for just $15 USD.
Summary
A new collaborative model of research is needed to increase resources, to prioritize the R&D agenda of the major public- and private-sector stakeholders, and ultimately to increase the probability and shorten the time to development of effective HIV vaccines for global use. The thrust of our proposal is (i) to increase the scale and organization for solving science problems and developing novel HIV vaccine approaches; (ii) to increase the pace, reduce the overlap, and more systematically explore the elements of and delivery systems for vaccines; (iii) to use common standards for the prompt comparative testing of vaccine candidates; (iv) to expand resources for manufacturing vaccine candidates to speed their use in human trials; and (v) to increase the capacity for international clinical trials and to focus this effort toward quickly measuring the effectiveness of vaccine protection as prototype vaccine candidates are identified.
